Tazarotene 0.045% Lotion for Treating PIE and PIH in Subjects With Acne

Inclusion Criteria: * Patient is male or female, 18-45 years of age inclusive at Screening. * Must have a facial IGA score of 2,3, or 4. * Minimum of 10 inflammatory lesions (papules, pustules, or nodules) in total on face (including nose). * Minimum of 20 PIE or PIH macules in total on face (including nose). * Skin phototype of I to VI on Fitzpatrick's scale. * Female subjects of childbearing potential must be on one of the following forms of birth control: a hormonal or non-hormonal IUD, an oral contraceptive pill that contains both estrogen and progestin, a contraceptive implant, or Depo shot. Patients will remain on the same contraception for 90 days prior to the baseline visit, for the duration of the study and for 1 month after. Exclusion Criteria: * More than 3 excoriated acne lesions. * Beard or extensive facial hair. * Female subject who is pregnant, nursing, or planning a pregnancy during the trial or within one month after last trial treatment application. * Isotretinoin within 90 days. * Other topical prescription retinoids (30 days wash out). * A new hormone or hormone regulating therapy (such as spironolactone or birth control), or change in an existing dosage, for any reason within 90 days prior to screening. A patient who has been using the same regimen for more than 90 days prior to the study may be enrolled but is expected to remain on said regimen for the duration of the study. * A new oral antibiotic or change in an existing dosage for any reason within…